ArticleJournal of gynecologic oncology2026
Cost-effectiveness of HPV catch-up vaccination program in women aged 13-24 years in a middle income country.
Article in Journal of gynecologic oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
objectiveThis study evaluated the cost-effectiveness of expanding the current routine human papillomavirus (HPV) vaccination program to women aged 13-24 years in Thailand.
methodsA Markov model of HPV infection and cervical cancer was adapted. We compared catch-up cohorts of 13- to 24-year-old women vaccinated with (1) bivalent HPV vaccine (Cervarix
resultsCompared to no vaccination, the catch-up vaccination programs decreased the incidence of cervical cancer cases and cancer-related deaths 44.8%-63.4% over a lifetime. Vaccinating with 2vHPV (Cervarix
conclusionAll catch-up vaccination programs for women aged 13 to 24 years produce additional health benefits and reduce healthcare costs. Vaccination with 9vHPV was considered the most cost-effective option.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.